Results 1 to 10 of about 10,672 (147)

Dolutegravir concentrations in children receiving 3-month weekly isoniazid and rifapentine (3HP) for tuberculosis prevention [PDF]

Microbiology Spectrum
In Tuberculosis Trials Consortium Study 35, which investigated the optimal dosing and safety of once-weekly isoniazid and rifapentine (3HP) in 69 children requiring tuberculosis preventive therapy, 7 children with HIV received 50 mg of once-daily ...
Ruvarashe J. Madzime, Louvina van der Laan, Samantha du Toit, Shaun Barnabas, Ingrid Courtney, Nicole E. Brown, Rada Savic, Belen P. Solans, Meredith G. Dixon, Lufina Tsirizani, Paolo Denti, Rosanna Boyd, Anneke C. Hesseling   +12 more
doaj   +2 more sources

Perceptions of dolutegravir-based regimen use among people living with HIV in Limpopo province: A qualitative study [PDF]

Curationis
Background: HIV and AIDS continues to be a critical public health challenge, with sub-Saharan Africa shouldering the heaviest burden. Progress towards disease management has been implemented over the years, and antiretroviral therapy (ART) has been the ...
Zandile R. Sibeko, Boitumelo J. Molato, Salaminah S.P. Moloko-Phiri   +2 more
doaj   +2 more sources

Acute interstitial nephritis due to dolutegravir: The first case reported

Nefrología (English Edition), 2023
Kidney disease is frequent in HIV-patients. We present a case of a 44-year-old woman, with known uncontrolled HIV infection and chronic kidney disease due to HIV-associated nephropathy.
Rui Barata, Bernardo Marques da Costa, David Navarro, Marco Mendes, Cecília Silva, Mário Góis, Helena Sousa, Fernando Nolasco   +7 more
doaj   +3 more sources

Virological Findings and Treatment Outcomes of Cases That Developed Dolutegravir Resistance in Malawi’s National HIV Treatment Program

Viruses, 2023
Millions of Africans are on dolutegravir-based antiretroviral therapy (ART), but few detailed descriptions of dolutegravir resistance and its clinical management exist.
Hope Kanise, Joep J. van Oosterhout, Pachawo Bisani, John Songo, Bilaal W. Matola, Chifundo Chipungu, Katherine Simon, Carrie Cox, Mina C. Hosseinipour, Jean-Batiste Sagno, Risa M. Hoffman, Claudia Wallrauch, Sam Phiri, Kim Steegen, Andreas Jahn, Rose Nyirenda, Tom Heller   +16 more
doaj   +1 more source

Effect of obesity on dolutegravir exposure in Black Southern African adults living with HIV

Southern African Journal of HIV Medicine, 2022
Background: Dolutegravir, a component of the preferred first-line antiretroviral therapy regimen, has been associated with increased weight gain. South Africa has a high prevalence of obesity, especially among women.
Enkosi Mondleki, Clifford G. Banda, Nomathemba C. Chandiwana, Simiso Sokhela, Lubbe Wiesner, Francois Venter, Gary Maartens, Phumla Z. Sinxadi   +7 more
doaj   +1 more source

Dolutegravir [PDF]

Hospital Pharmacy, 2014
Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing ...
Cada, Dennis J, Levien, Terri L, Baker, Danial E   +2 more
openaire   +3 more sources

Dolutegravir Discontinuation for Neuropsychiatric Symptoms in People Living with HIV and Their Outcomes after Treatment Change: A Pharmacogenetic Study

Metabolites, 2022
Neuropsychiatric symptoms have been reported in patients receiving dolutegravir, a known inhibitor of the renal and neuronal-expressed organic anion transporter 2 (encoded by SLC22A2 gene). The effect of the genetic variant SLC22A2 808C>A on dolutegravir
Jessica Cusato, Alberto Borghetti, Elisabetta Teti, Maurizio Milesi, Maria Cristina Tettoni, Stefano Bonora, Mattia Trunfio, Antonio D’Avolio, Mirko Compagno, Simona Di Giambenedetto, Giovanni Di Perri, Andrea Calcagno   +11 more
doaj   +1 more source

Standard versus double dose dolutegravir in patients with HIV-associated tuberculosis: a phase 2 non-comparative randomised controlled (RADIANT-TB) trial [version 1; peer review: 2 approved]

Wellcome Open Research, 2021
Dolutegravir, a second-generation integrase strand transfer inhibitor (InSTI), is replacing efavirenz as first-line antiretroviral therapy (ART) in low middle-income countries (LMICs).
Rulan Griesel, Andrew Hill, Graeme Meintjes, Gary Maartens   +3 more
doaj   +1 more source

Community acceptability of dolutegravir-based HIV treatment in women: a qualitative study in South Africa and Uganda

BMC Public Health, 2020
Background Despite concerns about dolutegravir use in pregnancy, most low- and middle-income countries are accelerating the introduction of dolutegravir-based regimens into national antiretroviral treatment programmes.
Yussif Alhassan, Adelline Twimukye, Thoko Malaba, Catherine Orrell, Landon Myer, Catriona Waitt, Mohammed Lamorde, Andrew Kambugu, Helen Reynolds, Saye Khoo, Miriam Taegtmeyer   +10 more
doaj   +1 more source

The risk of hyperglycaemia associated with the use of dolutegravir among adults living with HIV in Kampala, Uganda: a case-control study

The Lancet Global Health, 2022
Background: Emerging evidence suggests a possible association between hyperglycaemia and use of dolutegravir, a preferred first-line antiretroviral agent in sub-Saharan Africa.
Daphine Namara, MBChB, Jeremy I Schwartz, MD, Andrew K Tusubira, MPH, Willi McFarland, ProfMD, Caroline Birungi, MMed, Fred C Semitala, MMed, Martin Muddu, MMed   +6 more
doaj   +1 more source